The global intravenous immunoglobulin market size is expected to reach USD 24.13 billion by 2032, expected to grow at a CAGR of 7.50% during the forecast period.
The Intravenous Immunoglobulin (IVIG) Market focuses on the use of immunoglobulin therapy administered intravenously to treat a range of immune deficiencies and autoimmune diseases. IVIG contains a mixture of antibodies derived from the plasma of thousands of donors and is utilized for conditions such as primary and secondary immunodeficiency, immune thrombocytopenic purpura (ITP), Guillain-Barré Syndrome (GBS), and Kawasaki disease, among others.
Market Growth Drivers
- Rising Prevalence of Immune-Related Disorders
- The increasing global burden of immune deficiencies and autoimmune diseases, such as myasthenia gravis and chronic inflammatory demyelinating polyneuropathy (CIDP), drives demand for IVIG.
- Increasing Geriatric Population
- Older adults are more prone to immune dysfunction and chronic illnesses, contributing significantly to the growing utilization of IVIG therapies.
- Advancements in Plasma-Derived Therapies
- Innovations in plasma collection and fractionation have improved the quality, safety, and availability of IVIG, fostering market growth.
Some of the major players operating in the global market include:
- Baxter International Inc.
- BDI Pharma Inc.
- Biotest AG
- China Biologics Products Inc.
- CSL Behring
- Grifols SA
- Kedrion Biopharma
- LFB Biotechnologies
- Octapharma AG
Download Free Sample PDF Copy of the Report:
Key Trends in the IVIG Market
- Development of Subcutaneous Immunoglobulin (SCIG)
- While IVIG remains the standard, subcutaneous immunoglobulin (SCIG) offers advantages such as home-based administration, fueling competition and innovation in the market.
- Rising Plasma Collection Initiatives
- Governments and private organizations are increasing efforts to enhance plasma collection to meet the growing demand for IVIG therapies.
- Increasing Use in Neurological Disorders
- Neurological applications such as treating CIDP and GBS are gaining traction as IVIG proves effective in managing these conditions.
Recent Developments
- In March 2022, Sanofi and Seagen have signed an exclusive collaboration agreement to develop and commercialize up to three antibody-drug conjugates for cancer targets, using Sanofi’s monoclonal antibody technology and Seagen’s ADC technology.
- In January 2022, Argenx SE is a global immunology company that is dedicated to improving the quality of life for individuals suffering from severe autoimmune diseases. Recently, the Ministry of Health, Labour and Welfare (MHLW) in Japan has approved the use of VYVGART (efgartigimod alfa) intravenous infusion for the treatment of adult patients with generalized myasthenia gravis (gMG) who have not responded well to steroids or non-steroidal immunosuppressive therapies (ISTs).
𝐒𝐞𝐠𝐦𝐞𝐧𝐭𝐚𝐥 𝐀𝐧𝐚𝐥𝐲𝐬𝐢𝐬:
The research study includes segmental analysis that divides the market into distinct groups or segments based on common characteristics. With market segmentation, businesses can identify specific customer groups that are more likely to be interested in specific products or services. Also, it enables these businesses to focus their marketing efforts and resources more efficiently, leading to higher conversion rates and improved return on investment. Furthermore, segmentation analysis helps companies develop personalized products or services, which can result in increased customer loyalty and improved customer satisfaction.
Intravenous immunoglobulin, Component Outlook (Revenue – USD Billion, 2019 – 2032)
- IGG
- IGA
- IGM
- IGE
- IGD
Intravenous immunoglobulin, Route of Administration Outlook (Revenue – USD Billion, 2019 – 2032)
- Intravenous
- Subcutaneous
Intravenous immunoglobulin, Application Outlook (Revenue – USD Billion, 2019 – 2032)
- Hypogammaglobulinemia
- Chronic Inflammatory demyelinating polyneuropathy (CIDP)
- Immunodeficiency diseases
- Myasthenia Gravis
- Multifocal motor neuropathy
- Idiopathic thrombocytopenic purpura (ITP)
- Inflammatory myopathies
- Specific antibody deficiency
- Guillain-Barre syndrome
Intravenous immunoglobulin, End-Users Outlook (Revenue – USD Billion, 2019 – 2032)
- Hospitals
- Homecare
- Specialty Clinics
Intravenous immunoglobulin, Distribution channels Outlook (Revenue – USD Billion, 2019 – 2032)
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacies
The Intravenous Immunoglobulin (IVIG) Market is poised for significant growth, driven by rising prevalence of immune-related disorders, advancements in plasma therapies, and increasing adoption of immunoglobulin treatments worldwide. While challenges such as limited plasma supply and high costs persist, innovations in production processes, expanding applications, and rising awareness are expected to unlock new opportunities. With the increasing focus on improving patient outcomes and accessibility, the IVIG market will continue to play a critical role in managing immune and autoimmune diseases globally.